IGM Biosciences (IGMS)
(Delayed Data from NSDQ)
$16.16 USD
-1.07 (-6.21%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $16.40 +0.24 (1.49%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$16.16 USD
-1.07 (-6.21%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $16.40 +0.24 (1.49%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Zacks News
IGM Biosciences (IGMS) Surges 11.6%: Is This an Indication of Further Gains?
by Zacks Equity Research
IGM Biosciences (IGMS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
All You Need to Know About IGM Biosciences (IGMS) Rating Upgrade to Buy
by Zacks Equity Research
IGM Biosciences (IGMS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
IGM Biosciences, Inc. (IGMS) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
IGM Biosciences (IGMS) delivered earnings and revenue surprises of -2,733.33% and 97.58%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Urogen Pharma (URGN) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Urogen Pharma (URGN) delivered earnings and revenue surprises of -10.98% and 7.76%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Immunome, Inc. (IMNM) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Immunome (IMNM) delivered earnings and revenue surprises of -28.95% and 9.77%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
IGM Biosciences (IGMS) Soars 32.7%: Is Further Upside Left in the Stock?
by Zacks Equity Research
IGM Biosciences (IGMS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
IGM Biosciences, Inc. (IGMS) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
IGM Biosciences (IGMS) delivered earnings and revenue surprises of 1.19% and 30.30%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Soft Instrument Orders Likely to Hurt PacBio's (PACB) Q1 Earnings
by Zacks Equity Research
Despite strength in Revio and Onso platforms, an increasing number of customers delaying instrument purchases is likely to have dampened PacBio's (PACB) top line in the first quarter.
Intra-Cellular Therapies (ITCI) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Intra-Cellular (ITCI) delivered earnings and revenue surprises of 48.39% and 2.07%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Akoya Biosciences (AKYA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Akoya (AKYA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
IGM Biosciences, Inc. (IGMS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
IGM Biosciences (IGMS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
IGM Biosciences (IGMS) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
IGM Biosciences (IGMS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Analyzing How You Should Play Cigna (CI) Ahead of Q1 Earnings
by Zacks Equity Research
The first-quarter results of Cigna (CI) are likely to reflect expanding commercial middle market memberships and growth in Cigna Healthcare profits.
Nurix Therapeutics, Inc. (NRIX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Nurix Therapeutics (NRIX) delivered earnings and revenue surprises of 5% and 13.77%, respectively, for the quarter ended February 2024. Do the numbers hold clues to what lies ahead for the stock?
IGM Biosciences, Inc. (IGMS) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
IGM Biosciences, Inc. (IGMS) delivered earnings and revenue surprises of 4.72% and 31.47%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Wall Street Analysts Think IGM Biosciences, Inc. (IGMS) Could Surge 63.1%: Read This Before Placing a Bet
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 63.1% in IGM Biosciences, Inc. (IGMS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Strength Seen in iTeos Therapeutics, Inc. (ITOS): Can Its 7.4% Jump Turn into More Strength?
by Zacks Equity Research
iTeos Therapeutics, Inc. (ITOS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Wall Street Analysts Believe IGM Biosciences, Inc. (IGMS) Could Rally 35.08%: Here's is How to Trade
by Zacks Equity Research
The consensus price target hints at a 35.1% upside potential for IGM Biosciences, Inc. (IGMS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
IGM Bio (IGMS) Stock Rallies 142% in 3 Months: Here's Why
by Zacks Equity Research
IGM Bio (IGMS) stock surges 142% in the past three months on strategic reprioritization efforts to focus its resources on the development of pipeline candidates for cancer and autoimmune indications.
Does IGM Biosciences, Inc. (IGMS) Have the Potential to Rally 268.31% as Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 268.3% in IGM Biosciences, Inc. (IGMS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Orchard Therapeutics PLC Sponsored ADR (ORTX) Soars 12.9%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Orchard Therapeutics PLC Sponsored ADR (ORTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
IGM Biosciences, Inc. (IGMS) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
IGM Biosciences, Inc. (IGMS) delivered earnings and revenue surprises of 0% and 37.43%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in IGM Biosciences, Inc. (IGMS): Can Its 7.6% Jump Turn into More Strength?
by Zacks Equity Research
IGM Biosciences, Inc. (IGMS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
IGM Biosciences, Inc. (IGMS) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
IGM Biosciences, Inc. (IGMS) delivered earnings and revenue surprises of 2.92% and 70.89%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
IGM Biosciences, Inc. (IGMS) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
IGM Biosciences, Inc. (IGMS) delivered earnings and revenue surprises of 22.22% and 0.80%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?